October 16, 2015
FDA: Blood thinners can prevent strokes
Blood thinner (anticoagulant) can reduce the risk of a stroke by 50% to 60% for people who have atrial fibrillation.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 16, 2015
FDA approved Praxbind for patients taking Pradaxa
The U.S. Food and Drug Administration on Friday granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.
October 16, 2015
Onabotulinumtoxin A treatment decrease urinary incontinence in women
“These findings may help inform specialists treating patients with overactive bladder, that BOTOX is an effective and safe treatment option for patients not getting the relief from an anticholinergic.”
October 16, 2015
The Wolfson Institute and Premaitha Health: World first in-house antenatal reflex DNA screening
The Wolfson Institute of Preventive Medicine with the assistance of Premaitha Health plc , is launching an in-house antenatal reflex DNA screening service on 19 October 2015.
October 16, 2015
USA:Recall of lot # 45810 of Acetaminophen tablets
Medline Industries, Inc. announced that it will initiate a voluntary nationwide recall of lot # 45810 of Acetaminophen tablets, 500mg, uncoated compressed tablets to the consumer level.
October 15, 2015
BMS – Five Prime Agreement
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. have announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications.
October 15, 2015
‘Novartis Access’ in Kenya
Novartis has announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.
October 14, 2015
Eli Lilly and Company and Incyte Corporation: Positive Topline Results of RA-BEAM
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
October 14, 2015
Verona Pharma: Start of RPL554 Phase IIa combination study
Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).
October 14, 2015
Quantum Pharma:Licensing Agreement with Futura Medical
Quantum Pharma Plc has announced that it had signed an exclusive agreement with Futura Medical plc the healthcare company which is focused on advanced transdermal technology, to manufacture and make available MED2002, Futura’s novel treatment for erectile dysfunction, as an unlicensed medicine (special) in the UK (the “Agreement”).